Primary central nervous system dural-based anaplastic large cell lymphoma: Diagnostic considerations, prognostic factors, and treatment modalities

2017 ◽  
Vol 65 (2) ◽  
pp. 402 ◽  
Author(s):  
AmeyR Savardekar ◽  
MayurV Kaku ◽  
Yasha Muthane ◽  
A Arivazhagan ◽  
MallaBhaskara Rao
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Prognostic Factors ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Treatment Modalities ◽  
Large Cell Lymphoma

scholarly journals Clinical Features and Prognostic Factors for Primary Anaplastic Large Cell Lymphoma of the Central Nervous System: A Systematic Review

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4358
Author(s):  
Yudai Hirano ◽  
Satoru Miyawaki ◽  
Shota Tanaka ◽  
Kazuki Taoka ◽  
Hiroki Hongo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Central Nervous System ◽  
Nervous System ◽  
Prognostic Factors ◽  
Clinical Features ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
The Central Nervous System ◽  
Large Cell Lymphoma

Primary anaplastic large cell lymphoma (ALCL) of the central nervous system (CNS) is a subtype of primary CNS lymphoma (PCNSL). There are very few comprehensive reports on this extremely rare tumor. Therefore, it is necessary to investigate the clinical features and prognostic factors for primary ALCL of the CNS. We performed a systematic review of the published literature. Past cases were comprehensively searched using PubMed, Cochrane Library, and Web of Science. Clinical information, such as age, sex, anaplastic lymphoma kinase (ALK) status, lesion sites, treatment methods, and survivorship were extracted. Thirty-nine cases with information on ALK status and treatment course were identified. The average observation period was 13 months, and the overall 2-year survival rate was 58%. Univariate analyses showed a statistically significantly better prognosis among patients < 40 years of age (p = 0.039, HR 0.32 (0.11–0.95)) and in relation to ALK positivity (p = 0.010, HR 0.24 (0.08–0.71) and methotrexate treatment (p = 0.003, HR 0.17 (0.05–0.56)). Because of the sparsity of cases, it is necessary to accumulate cases in order to perform more detailed analyses.

Primary Central Nervous System Anaplastic Large Cell Lymphoma is an Unusual Brain Tumour

2014 ◽  
Vol 10 (01) ◽  
pp. 48
Author(s):  
Dionysis Papadatos-Pastos ◽  
James Hall ◽  
Ruth Pettengell ◽  
Leslie R Bridges ◽  
Barry Newell ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Anaplastic Large Cell Lymphoma ◽  
Potential Role ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Anaplastic Lymphoma ◽  
The Central Nervous System ◽  
Large Cell Lymphoma

We present a case of a 64-year-old man who was diagnosed with a primary anaplastic large cell lymphoma of the central nervous system (PCNSAL). He had received radical chemotherapy and radiotherapy for a non-small cell lung cancer (NSCLC) in the past. There is no known association between NSCLC and PCNSAL. We describe the diagnostic and therapeutic challenges associated with these rare intracranial lymphomas and highlight the potential role of newer biological agents in patients with anaplastic lymphoma kinase (ALK-1) positive PCNSAL.

scholarly journals Pediatric Anaplastic Large Cell Lymphoma with Concomitant Involvement of Spine and Central Nervous System: A Case Report and Review of Literature

Hemato ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. 586-595
Author(s):  
Giulia A. Restivo ◽  
Lara Mussolin ◽  
Paolo D’Angelo ◽  
Angela Trizzino ◽  
Salvatore Ialuna ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Anaplastic Large Cell Lymphoma ◽  
Residual Disease ◽  
Cell Lymphoma ◽  
Early Recognition ◽  
Fusion Transcript ◽  
Large Cell ◽  
Anaplastic Lymphoma ◽  
Large Cell Lymphoma

Anaplastic large cell lymphoma (ALCL) is a histological subtype of non-Hodgkin lymphoma, largely characterized by anaplastic lymphoma kinase (ALK) positivity, resulting from the chromosomal translocation t(2;5). We report a pediatric case of ALK-positive ALCL with primary concomitant involvement of bone and central nervous system (CNS); thereafter, a literature review about pediatric primary bone and primary CNS ALCL was conducted. According to the analyzed data, our case is unique because it is characterized by the contemporary involvement of the spine and CNS. During and after chemotherapy, our patient was monitored by detecting minimal residual disease (MRD) through the analysis of fusion transcript nucleophosmin-ALK. MRD assessment, not only in bone marrow but also in peripheral blood, seems to be a very powerful tool for predicting the prognosis of pediatric ALCL patients, as already described in the literature. Moreover, as shown in our case, it could be used during the follow-up for early recognition of relapse.

Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib

2019 ◽  
Vol 83 ◽  
pp. 106164 ◽  
Author(s):  
Samuel B. Tomlinson ◽  
Stephen Sandwell ◽  
Sally T. Chuang ◽  
Mahlon D. Johnson ◽  
G. Edward Vates ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Central Nervous System Relapse ◽  
Large Cell Lymphoma
Sign in / Sign up

Export Citation Format

Share Document